Metformin in Breast Cancer, Visualized With Positron Emission Tomography

Aarhus University Hospital

Status and phase: Completed; Phase 1

Conditions: Breast Cancer

Treatments: Radiation: 11C-metformin

Study type: Interventional

Funder types: Other

Identifiers

NCT02882581

2016-000132-18

Details and patient eligibility

About

The general purpose of the trial is to investigate whether metformin is taken up into the breast tumor. Studies in the last few years have shown an effect of metformin on cell proliferation on breast cancer. It is though unclear whether the effect on tumor is direct, indirect or a combination of the two. The investigators plan to:

• investigate if metformin is taken up in breast cancer using our novel 11C-metformin tracer and positron emission tomography (PET)
• investigate whether the uptake is correlated to the amounts of organic cation transporters (OCT1-3, MATE 1 &2 and PMAT) using quantitive polymerase chain reaction (qPCR).

Enrollment: 7 patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• over 50 years
• C. mammae
• Tumor size: > 10 mm in diameter
• Unilateral cancer
• WHO performance status 0-1

Exclusion criteria

• Severe heart- or kidney failure
• Pregnant or breast feeding
• If the patient is found not eligible for participation in the study på principal investigator

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

11C-metformin

Experimental group

Description:

All participants allocated to the study will be included in this arm

Treatment:

Radiation: 11C-metformin